In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

EJNMMI Research

Volumn 1, Issue 1, 2011, Pages 1-15

  Wong, Karen J ^a   Baidoo, Kwamena E ^a   Nayak, Tapan K ^a   Garmestani, Kayhan ^a   Brechbiel, Martin W ^a   Milenic, Diane E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB')2 FRAGMENT; INDIUM 111; PANITUMUMAB; PENTETIC ACID; YTTRIUM 86;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DETERMINATION; FEMALE; GAMMA SCINTIGRAPHY; IC 50; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIMIT OF QUANTITATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR IMAGING; MOLECULAR MODEL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY;

EID: 84863233334     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-1-1     Document Type: Article

References (54)

1. Khawli LA, Biela BH, Hu PS, Epstein AL: Stable, genetically engineered F (ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. Hybrid Hybridomics 2002, 21:11-8.
2. Britton KE: The development of new radiopharmaceuticals. Eur J Nucl Med 1990, 16:373-85.
3. Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, et al: Tc-99m-labeled divalent and tetravalent CC49 singlechain Fv's: Novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 2001, 42:1519-27.
4. Jain RK: Transport of Molecules in the Tumor Interstitium-A Review. Cancer Res 1987, 47:3039-51.
5. Milenic DE, Detrick B, Reynolds JC, Colcher D: Characterization of primate antibody responses to administered murine monoclonal immunoglobulin. Int J Biol Markers 1990, 5:177-87.
6. Primus FJ, Bennett SJ, Kim EE, Deland FH, Zahn MC, Goldenberg DM: Circulating Immune-Complexes in Cancer Patients Receiving Goat Radiolocalizing Antibodies to Carcinoembryonic Antigen. Cancer Res 1980, 40:497-501.
7. Yokota T, Milenic DE, Whitlow M, Schlom J: Rapid Tumor Penetration of a Single-Chain Fv and Comparison with other Immunoglobulin Forms. Cancer Res 1992, 52:3402-8.
8. Nisonoff A, Wissler FC, Lipman LN, Woernley DL: Separation of Univalent Fragments from the Bivalent Rabbit Antibody Molecule by Reduction of Disulfide Bonds. Arch Biochem Biophys 1960, 89:230-44.
9. Hasemann CA, Capra JD: Immunoglobulins: Structure and Function. In Fundamental Immunology. Second edition. Edited by: Paul WE. New York: Raven Press; 1989:209-33.
10. Milenic DE, Esteban JM, Colcher D: Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. Journal of Immunological Methods 1989, 120:71-83.
11. Milenic DE: Radioimmunotherapy: Designer molecules to potentiate effective therapy. Seminars in Radiation Oncology 2000, 10:139-55.
12. Colcher D, Zalutsky M, Kaplan W, Kufe D, Austin F, Schlom J: Radiolocalization of Human Mammary-Tumors in Athymic Mice by a Monoclonal-Antibody. Cancer Res 1983, 43:736-42.
13. Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, et al: Construction, Binding Properties, Metabolism, and Tumor Targeting of a Single-Chain Fv Derived from the Pancarcinoma Monoclonal Antibody CC49. Cancer Res 1991, 51:6363-71.
14. 2. J Nucl Med 1983, 24:316-25.
15. 2, and Fab' in Mice. Cancer Res 1986, 46:3969-78.
16. Wu AM: Antibodies and Antimatter: The Resurgence of Immuno-PET. J Nucl Med 2009, 50:2-5.
17. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J: Microautoradiographic Analysis of the Normal Organ Distribution of Radioiodinated Single-Chain Fv and other Immunoglobulin Forms. Cancer Res 1993, 53:3776-83.
18. Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR: Human/murine chimeric 8 1C6 F(ab)(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nuclear Medicine and Biology 2004, 31:345-55.
19. 2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1986, 77:301-11.
20. Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, et al: Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. J Oncol 2010, 2010:394913.
21. Yang XD, Jia XC, Corvalan JRF, Wang P, Davis CG: Development of ABXEGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol/Hematol 2001, 38:17-23.
22. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R: FDA drug approval summary: Panitumumab (Vectibix (TM). Oncologist 2007, 12:577-83.
23. Rowinsky E, Schwartz G, Dutcher J, Vogelzang N, Gollob J, Thompson J, et al: ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: phase II clinical trial in renal cell cancer (RCC). Eur J Cancer 2002, 38:178.
24. Liu Z, Liu Y, Jia B, Zhao H, Jin X, Li F, et al: Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther 2010, 9:2297-308.
25. Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, et al: Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol 2009, 157:1541-8.
26. Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW: HER1-Targeted Y-Panitumumab Possesses Superior Targeting Characteristics than Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts. PLoS One 2011, 6:e18198.
27. Nayak TK, Regino CAS, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, et al: PET imaging of HER1-expressing xenografts in mice with Y-86-CHX-A"-DTPA-cetuximab. European Journal of Nuclear Medicine and Molecular Imaging 2010, 37:1368-76.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein Measurement with the Folin Phenol Reagent. Journal of Biological Chemistry 1951, 193:265-75.
29. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, et al: Cetuximab: Preclinical Evaluation of a Monoclonal Antibody Targeting EGFR for Radioimmunodiagnostic and Radioimmunotherapeutic Applications. Cancer Biotherapy and Radiopharmaceuticals 2008, 23:619-31.
30. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, et al: Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(pnitrobenzyl)-trans-CyDTPA. Bioorganic & Medicinal Chemistry 1997, 5:1925-34.
31. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW: Spectrophotometric method for determination of a bifunctional DTPA ligand in DTPA monoclonal-antibody conjugates. Bioconjugate Chem 1992, 3:342-5.
32. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW: A new and convenient method for purification of Y-86 using a Sr(II) selective resin and comparison of biodistribution of Y-86 and In-111 labeled Herceptin (TM). Nuclear Medicine and Biology 2002, 29:599-606.
33. Fraker PJ, Speck JC Jr: Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6adiphrenylglycoluril. Biochem Biophys Res Commun 1978, 80:849-57.
34. Xu H, Baidoo K, Gunn AJ, Boswell CA, Milenic DE, Choyke PL, et al: Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence Imaging agent for monoclonal antibody tumor-targeted imaging. Journal of Medicinal Chemistry 2007, 50:4759-65.
35. Xi W, Seidel J, Kakareka JW, Pohida TJ, Milenic DE, Proffitt J, et al: MONICA: a compact, portable dual gamma camera system for mouse whole-body imaging. Nuclear Medicine and Biology 2010, 37:245-53.
36. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW: Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with Y-86 for Quantitative PET of Carcinoma. J Nucl Med 2010, 51:942-50.
37. Smith-Jones PM, Solit DB, Akhurst T, Afronze F, Rosen N, Larson SM: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004, 22:701-6.
38. Tabrizi MA, Tseng CML, Roskos LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11:81-8.
39. Olafsen T, Wu AM: Antibody Vectors for Imaging. Semin Nucl Med 2010, 40:167-81.
40. Tolmachev V: Imaging of HER-2 Overexpression in Tumors for Guiding Therapy. Curr Pharm Design 2008, 14:2999-3019.
41. Milenic D, Garmestani K, Dadachova E, Chappell L, Albert P, Hill D, et al: Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 2004, 19:135-47.
42. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma DS, et al: In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with Lu-177 for radioimmunotherapeutic applications. Nuclear Medicine and Biology 2002, 29:431-42.
43. Milenic DE, Roselli M, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, et al: In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biotherapy and Radiopharmaceuticals 2001, 16:133-46.
44. 2 fragments of IgG1, IgG2, and IgG4 sub-class in vivo. Int J Cancer 1992, 50:416-22.
45. Burvenich IJG, Schoonooghe S, Blanckaert P, Bacher K, Vervoort L, Coene E, et al: Biodistribution and planar gamma camera imaging of I-123-and I-131-labeled F(ab ')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nuclear Medicine and Biology 2007, 34:257-65.
46. Ober RJ, Radu CG, Ghetie V, Ward ES: Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001, 13:1551-9.
47. Grunberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Blauenstein P, et al: In vivo evaluation of Lu-177-and Cu-67/64-labelled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clinical Cancer Research 2005, 11:5112-20.
48. Niu G, Li Z, Xie J, Le QT, Chen X: PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009, 50:1116-23.
49. Villaraza AJ, Milenic DE, Brechbiel MW: Improved Speciation Characteristics of PEGylated Indocyanine Green-Labeled Panitumumab: Revisiting the Solution and Spectroscopic Properties of a Near-Infrared Emitting anti-HER1 Antibody for Optical Imaging of Cancer. Bioconjug Chem 2010, 21(12):2305-12.
50. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, et al: Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991, 83:97-104.
51. Schechter NR, Wendt RE, Yang DJ, Azhdarinia A, Erwin WD, Stachowiak AM, et al: Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2004, 45:1683-7.
52. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al: High affinity restricts the localization and tumor penetration of singlechain Fv antibody molecules. Cancer Res 2001, 61:4750-5.
53. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, et al: Avidity-mediated enhancement of in vivo tumor targeting by singlechain Fv dimers. Clin Cancer Res 2006, 12:1599-605.
54. McCabe KE, Wu AM: Positive progress in immunoPET-not just a coincidence. Cancer Biother Radiopharm 2010, 25:253-61.